Piriformis Syndrome Market Research Report Information By Cause (Trauma, Spasms, Others), Diagnostic Test (MRI, Others), Treatment (Medication, Physical Therapy, Others), Distribution Channel (Retail Pharmacies, Others), End-User – Forecast Till 2030

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Piriformis Syndrome Market, by Cause

6.1 Introduction

6.2 Trauma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Spasms

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Overuse Injury

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Piriformis Syndrome Market, by Diagnostic Test

7.1 Introduction

7.2 Magnetic Resonance Imaging (MRI)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Computed Tomography (CT)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 X-rays

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 Neurophysiologic Testing

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.6 Electromyography (EMG)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.7 Beatty Test

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.8 FAIR (Flexion, adduction, and Internal Rotation) Test

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.9 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Piriformis Syndrome Market, by Treatment

8.1 Introduction

8.2 Medications

8.2.1 NSAIDs

8.2.1.1 Naproxen

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.1.2 Ibuprofen

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.1.3 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.2 Piriformis Muscle Injection

8.2.2.1 Botox Injection

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.2.2 Steroid Injection

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.2.3 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Physical Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Acupuncture

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5 Prolotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.6 Osteopathic Manipulative Treatment (OMT)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.7 Surgery

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.7 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Piriformis Syndrome Market, by Distribution Channel

9.1 Introduction

9.2 E-Commerce

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.3 Retail Pharmacies

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.4 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 10. Global Piriformis Syndrome Market, by End-User

10.1 Introduction

10.2 Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

10.3 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

10.4 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 11. Global Piriformis Syndrome Market, by Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 US

11.2.1.2 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 UK

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia-Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia-Pacific

11.5 The Middle East & Africa

11.5.1 The Middle East

11.5.2 Africa

Chapter 12. Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

Chapter 13. Company Profiles

13.1 Bayer AG

13.1.1 Company Overview

13.1.2 Product Overview

13.1.3 Financials Overview

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.2 Novartis AG

13.2.1 Company Overview

13.2.2 Product Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 AstraZeneca

13.3.1 Company Overview

13.3.2 Product Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Endo Pharmaceuticals

13.4.1 Company Overview

13.4.2 Technology/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Teva Pharmaceuticals

13.5.1 Company Overview

13.5.2 Product Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.6 Omron Healthcare

13.6.1 Company Overview

13.6.2 Product Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.7 Sanofi S.A.

13.7.1 Overview

13.7.2 Product Overview

13.7.3 Financial Overview

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 DePuy Synthes Companies

13.8.1 Overview

13.8.2 Product/ Technology Overview

13.8.3 Financials

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.9 Miracle Stretch, LLC

13.9.1 Overview

13.9.2 Product Overview

13.9.3 Financials

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.10 Flex Pharma, Inc.

13.10.1 Overview

13.10.2 Product Overview

13.10.3 Financials

13.10.4 Key Developments

13.10.5 SWOT Analysis

13.11 Nidd Valley Medical

13.11.1 Overview

13.11.2 Product Overview

13.11.3 Financials

13.11.4 Key Developments

13.11.5 SWOT Analysis

13.12 SEIRIN Corporation

13.12.1 Overview

13.12.2 Product Overview

13.12.3 Financials

13.12.4 Key Developments

13.12.5 SWOT Analysis

13.13 Others

13.13.1 Overview

13.13.2 Product Overview

13.13.3 Financials

13.13.4 Key Developments

13.13.5 SWOT Analysis

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Prediction of the Global Piriformis Syndrome Industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Global Piriformis Syndrome Market Synopsis, 2020–2027

Table 2 Global Piriformis Syndrome Market Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Global Piriformis Syndrome Market, by Region, 2020–2027, (USD Million)

Table 4 Global Piriformis Syndrome Market, by Cause, 2020–2027, (USD Million)

Table 5 Global Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD Million)

Table 6 Global Piriformis Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 7 Global Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD Million)

Table 8 Global Piriformis Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 9 North America Piriformis Syndrome Market, by Cause, 2020–2027, (USD

Million)

Table 10 North America Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD

Million)

Table 11 North America Piriformis Syndrome Market, by Treatment, 2020–2027, (USD

Million)

Table 12 North America Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD

Million)

Table 13 North America Piriformis Syndrome Market, by End-User, 2020–2027, (USD

Million)

Table 14 US Piriformis Syndrome Market, by Cause, 2020–2027, (USD Million)

Table 15 US Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD Million)

Table 16 US Piriformis Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 17 US Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD Million)

Table 18 US Piriformis Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 19 Canada Piriformis Syndrome Market, by Cause, 2020–2027, (USD Million)

Table 20 Canada Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD Million)

Table 21 Canada Piriformis Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 22 Canada Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD Million)

Table 23 Canada Piriformis Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 24 South America Piriformis Syndrome Market, by Cause, 2020–2027, (USD Million)

Table 25 South America Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD

Million)

Table 26 South America Piriformis Syndrome Market, by Treatment, 2020–2027, (USD

Million)

Table 27 South America Piriformis Syndrome Market, by Distribution Channel, 2020–2027,

(USD Million)

Table 28 South America Piriformis Syndrome Market, by End-User, 2020–2027, (USD

Million)

Table 29 Europe Piriformis Syndrome Market, by Cause, 2020–2027, (USD Million)

Table 30 Europe Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD Million)

Table 31 Europe Piriformis Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 32 Europe Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD

Million)

Table 33 Europe Piriformis Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 34 Western Europe Piriformis Syndrome Market, by Cause, 2020–2027, (USD

Million)

Table 35 Western Europe Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD

Million)

Table 36 Western Europe Piriformis Syndrome Market, by Treatment, 2020–2027,

(USD Million)

Table 37 Western Europe Piriformis Syndrome Market, by Distribution Channel, 2020–2027,

(USD Million)

Table 38 Western Europe Piriformis Syndrome Market, by End-User, 2020–2027, (USD

Million)

Table 39 Eastern Europe Piriformis Syndrome Market, by Cause, 2020–2027, (USD

Million)

Table 40 Eastern Europe Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD

Million)

Table 41 Eastern Europe Piriformis Syndrome Market, by Treatment, 2020–2027,

(USD Million)

Table 42 Eastern Europe Piriformis Syndrome Market, by Distribution Channel, 2020–2027,

(USD Million)

Table 43 Eastern Europe Piriformis Syndrome Market, by End-User, 2020–2027, (USD

Million)

Table 44 Asia-Pacific Piriformis Syndrome Market, by Cause, 2020–2027, (USD

Million)

Table 45 Asia-Pacific Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD

Million)

Table 46 Asia-Pacific Piriformis Syndrome Market, by Treatment, 2020–2027, (USD

Million)

Table 47 Asia-Pacific Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD

Million)

Table 48 Asia-Pacific Piriformis Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 49 Middle East & Africa Piriformis Syndrome Market, by Cause, 2020–2027,

(USD Million)

Table 50 Middle East & Africa Piriformis Syndrome Market, by Diagnostic Test, 2020–2027,

(USD Million)

Table 51 Middle East & Africa Piriformis Syndrome Market, by Treatment, 2020–2027,

(USD Million)

Table 52 Middle East & Africa Piriformis Syndrome Market, by Distribution Channel, 2020–2027,

(USD Million)

Table 53 Middle East & Africa Piriformis Syndrome Market, by End-User, 2020–2027, (USD

Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Piriformis Syndrome Market

Figure 3 Segmentation Market Dynamics for Global Piriformis Syndrome Market

Figure 4 Global Piriformis Syndrome Market Share, by Cause, 2020

Figure 5 Global Piriformis Syndrome Market Share, by Diagnostic Test, 2020

Figure 6 Global Piriformis Syndrome Market Share, by Treatment, 2020

Figure 7 Global Piriformis Syndrome Market Share, by Distribution Channel, 2020

Figure 8 Global Piriformis Syndrome Market Share, by End-User, 2020

Figure 9 Global Piriformis Syndrome Market Share, by Region, 2020

Figure 10 North America Piriformis Syndrome Market Share, by Country, 2020

Figure 11 Europe Piriformis Syndrome Market Share, by Country, 2020

Figure 12 Asia-Pacific Piriformis Syndrome Market Share, by Country, 2020

Figure 13 Middle East & Africa Piriformis Syndrome Market Share, by Country, 2020

Figure 14 Global Piriformis Syndrome Market: Company Share Analysis, 2020 (%)

Figure 15 Bayer AG: Key Financials

Figure 16 Bayer AG: Segmental Revenue

Figure 17 Bayer AG: Geographical Revenue

Figure 18 Novartis AG: Key Financials

Figure 19 Novartis AG: Segmental Revenue

Figure 20 Novartis AG: Geographical Revenue

Figure 21 AstraZeneca:: Key Financials

Figure 22 AstraZeneca: Segmental Revenue

Figure 23 AstraZeneca: Geographical Revenue

Figure 24 Endo Pharmaceuticals: Key Financials

Figure 25 Endo Pharmaceuticals: Segmental Revenue

Figure 26 Endo Pharmaceuticals: Geographical Revenue

Figure 27 Teva Pharmaceuticals: Key Financials

Figure 28 Teva Pharmaceuticals: Segmental Revenue

Figure 29 Teva Pharmaceuticals. Geographical Revenue

Figure 30 Omron Healthcare: Key Financials

Figure 31 Omron Healthcare: Segmental Revenue

Figure 32 Omron Healthcare: Geographical Revenue

Figure 33 Sanofi S.A.: Key Financials

Figure 34 Sanofi S.A.: Segmental Revenue

Figure 35 Sanofi S.A.: Geographical Revenue

Figure 36 DePuy Synthes Companies: Key Financials

Figure 37 DePuy Synthes Companies: Segmental Revenue

Figure 38 DePuy Synthes Companies: Geographical Revenue

Figure 39 Miracle Stretch, LLC: Key Financials

Figure 40 Miracle Stretch, LLC: Segmental Revenue

Figure 41 Miracle Stretch, LLC: Geographical Revenue

Figure 42 Flex Pharma, Inc.: Key Financials

Figure 43 Flex Pharma, Inc.: Segmental Revenue

Figure 44 Flex Pharma, Inc.: Geographical Revenue

Figure 45 Nidd Valley Medical: Key Financials

Figure 46 Nidd Valley Medical Segmental Revenue

Figure 47 Nidd Valley Medical: Geographical Revenue

Figure 48 SEIRIN Corporation: Key Financials

Figure 49 SEIRIN Corporation: Segmental Revenue

Figure 50 SEIRIN Corporation: Geographical Revenue